Please assess the completion status of the following clinical trial:

Trial Title: AHN-12 Biodistribution in Advanced Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have one of the following histologically confirmed CD45+ diseases. If possible, AHN-12 positivity will be confirmed by flow cytometry on a recent bone marrow or a peripheral blood sample, if circulating blasts are present.~  * Acute myelogenous leukemia (AML), primary refractory or relapsed disease~ * Refractory myelodysplastic syndrome (MDS)~ * AML arising from pre-existing MDS, refractory~ * Acute lymphoblastic leukemia (ALL), primary refractory or relapsed disease~ * Chronic myelogenous leukemia (CML) following blast crisis~* Age ≥ 12 years~* Karnofsky Performance Status ≥ 60% (16 years and older) or Lansky Play Score ≥ 60 (\<16 years)~* Life expectancy of \> 12 weeks in the opinion of the enrolling medical provider~* Patients must have adequate organ function~* Human anti-mouse antibody (HAMA) must be negative (perform on all patients regardless of prior therapies).~* Consent to adequate contraception. The effects of 90Y-AHN-12 on the developing fetus are unknown.~* Source of allogeneic stem cells must have been identified in event of severe myelosuppression~* Able to give written consent.~* Both men and women of all ethnic groups are eligible for this trial.~Exclusion Criteria:~* Ongoing grade 2 or greater non-hematologic toxicity due to previously administered therapies~* \< 8 days from completion of therapy with any biologic agent~* Receiving any investigational agents~* Active central nervous system (CNS) leukemia are excluded from this clinical trial~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to 90Y-AHN-12 or other agents used in study.~* Uncontrolled illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the opinion of the enrolling medical provider.~* Pregnant and breastfeeding women are excluded from this study because 90Y-AHN-12, being radioactive, as well as high dose chemotherapy and total body irradiation (TBI) have the potential for teratogenic or abortifacient effects.~* Human immunodeficiency virus (HIV) positive patients:~* \< 60 days since an autologous transplant~* Bone marrow cellularity \<5% (because of concern of myelosuppression)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- receiving AHN-12 and 90Y-AHN-12 (Type: EXPERIMENTAL): Patients receiving nonradiolabeled cold AHN-12 (.20 mg/kg to 1.0 mg/kg) of at least one dose and up to a total of 3 dosimetry infusions (intervals no sooner than 8 days and up to 21 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).